Nuvation Bio Inc - Asset Resilience Ratio
Nuvation Bio Inc (NUVB) has an Asset Resilience Ratio of 54.04% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Nuvation Bio Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Nuvation Bio Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Nuvation Bio Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Nuvation Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore NUVB strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $402.35 Million | 54.04% |
| Total Liquid Assets | $402.35 Million | 54.04% |
Asset Resilience Insights
- Very High Liquidity: Nuvation Bio Inc maintains exceptional liquid asset reserves at 54.04% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nuvation Bio Inc Industry Peers by Asset Resilience Ratio
Compare Nuvation Bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Celldex Therapeutics Inc
NASDAQ:CLDX |
Biotechnology | 81.32% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Savara Inc
NASDAQ:SVRA |
Biotechnology | 68.30% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
Annual Asset Resilience Ratio for Nuvation Bio Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Nuvation Bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 61.38% | $365.12 Million | $594.82 Million | -24.99pp |
| 2024-12-31 | 86.38% | $466.97 Million | $540.63 Million | -5.11pp |
| 2023-12-31 | 91.48% | $568.56 Million | $621.48 Million | +8.18pp |
| 2022-12-31 | 83.30% | $559.91 Million | $672.14 Million | +1.75pp |
| 2021-12-31 | 81.55% | $632.97 Million | $776.15 Million | -2.31pp |
| 2020-12-31 | 83.86% | $186.00 Million | $221.79 Million | -11.55pp |
| 2019-12-31 | 95.41% | $115.40 Million | $120.95 Million | -- |
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the ma… Read more